Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer.
Saved in:
| Title: | Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer. |
|---|---|
| Authors: | Zeller T; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany., Münnich IA; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany., Windisch R; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany., Hilger P; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany., Schewe DM; Medical Faculty, Otto-von-Guericke University Magdeburg, Magdeburg, Germany., Humpe A; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany., Kellner C; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany. |
| Source: | Frontiers in immunology [Front Immunol] 2023 Sep 13; Vol. 14, pp. 1240275. Date of Electronic Publication: 2023 Sep 13 (Print Publication: 2023). |
| Publication Type: | Journal Article; Review; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
